The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 03, 2020

Filed:

Mar. 18, 2019
Applicant:

University of Pittsburgh—of the Commonwealth System of Higher Education, Pittsburgh, PA (US);

Inventors:

Jianhua Luo, Wexford, PA (US);

Yanping Yu, Wexford, PA (US);

Zhanghui Chen, Hangzhou, CN;

George Konstantine Michalopoulos, Pittsburgh, PA (US);

Joel Nelson, Pittsburgh, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/90 (2006.01); C12Q 1/6886 (2018.01); C12N 15/63 (2006.01); C12N 15/11 (2006.01); A61K 31/522 (2006.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01); C12N 9/12 (2006.01); C12N 9/22 (2006.01);
U.S. Cl.
CPC ...
C12N 15/907 (2013.01); A61K 31/522 (2013.01); A61K 38/1761 (2013.01); A61K 48/0058 (2013.01); C12N 9/1211 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/63 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/01021 (2013.01); C12N 2310/10 (2013.01); C12N 2310/20 (2017.05); C12Q 2600/156 (2013.01);
Abstract

The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of 'progressive prostate cancer'), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.


Find Patent Forward Citations

Loading…